A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 10, 1998, Pages 965-971

  Van Hoogstraten, H J F ^a   De Smet, M B M ^b   Renooij, W ^b   Breed, J G S ^c   Engels, L G J B ^d   Den Ouden Muller, J W ^e   Rijk, M C M ^f   Smit, A M ^g   Zwertbroek, R ^c   Hop, W C J ^h   Van Berge Henegouwen, G P ^b   Schalm, S W ^a   Van Buuren, H R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c St Jans Gasthuis ^*  (Netherlands)

^d Sittard Geleen Heerlen   (Netherlands)

^e SINT FRANCISCUS GASTHUIS   (Netherlands)

^f Ziekenhuis de Baronie   (Netherlands)

^g JEROEN BOSCH HOSPITAL   (Netherlands)

^h ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN M; URSODEOXYCHOLIC ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DUODENUM; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; SYMPTOM;

ADULT; AGED; BILE ACIDS AND SALTS; CHOLAGOGUES AND CHOLERETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 7344229937     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00395.x     Document Type: Article

References (47)

1. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 1570-80.
2. Gershwin ME. The molecular basis of primary biliary cirrhosis: interfacing clinical medicine and wet bench research. Isr J Med Sci 1995; 31: 22-30.
3. Sherlock S. Primary biliary cirrhosis: clarifying the issues. Am J Med 1994; 96: S27-33.
4. Lindor KID, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110: 1515-18.
5. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UCA-PBC Study Group. N Engl J Med 1994; 330: 1342-7.
6. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-56.
7. Combes B, Carithers R Jr, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995: 22: 759-66.
8. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-90.
9. Podda M, Ghezzi C, Battezzati PM, et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 1989; 34: S59-65.
10. Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834-6.
11. Eriksson LS, Olsson R, Glauman H, et al. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. Scand J Gastroenterol 1997; 52: 179-86.
12. Battezzati PM, Podda M, Bianchi FB, et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. J Hepatol 1995; 17: 332-8.
13. Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, James OF. A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 1994; 9: 162-8.
14. Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268-74.
15. Wolfhagen FHJ, van Buuren HR, Schalm SW, et al. Can ursodeoxycholic acid induce disease remission in primary biliary cirrhosis? The Dutch Multicentre PBC Study Group. J Hepatol 1995; 22: 381.
16. Taal BG, Schalm SW, ten Kate FW, Hermans J, Geertzen RG, Hellkamp BE. Clinical diagnosis of primary biliary cirrhosis: a classification based on major and minor criteria. Hepatogastroenterology 1983; 30: 178-82.
17. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
18. Vonk RJ, Kneepkens CM, Havinga R, Kuipers F, Bijleveld CM. Enterohepatic circulation in man. A simple method for the determination of duodenal bite acids. J Lipid Res 1986; 27: 901-4.
19. Rosenthal P. Collection of duodenal bile in infants and children by the siring test. J Pediatr Gastroenterol Nutr 1985; 4: 284-5.
20. Turley SD, Dietschy JM. Re-evaluation of the 3 alpha-hydroxysteroid dehydrogenase assay for total bile acids in bile. J Lipid Res 1978; 19: 924-8.
21. Setchell KD, Matsui A. Serum bile acid analysis. Clin Chim Acta 1983; 127: 1-17.
22. Kuipers F, Spanjer HH, Havinga R, Scherphof GL, Vonk RJ. Lipoproteins and liposomes as in vivo cholesterol vehicles in the rat: preferential use of cholesterol carried by small unilamellar liposomes for the formation of muricholic acids. Biochim Biophys Acta 1986; 876: 559-66.
23. Mitchell S, Bansi D, Hunt N, Christie J, Fleming K, Chapman R. High close ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): Results after two years of a randomised double-blind, placebo-controlled trial. Gastroenterology 1997; 1 12(Suppl.): A1335(Abstract).
24. van de Meeberg PC, Houwen RH, Sinaasappel M, Heijerman HG, Bijleveld CM, Vanberge-Henegouwen GP. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol 1997; 32: 369-73.
25. Colombo C, Crosignani A, Assaisso M, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 1992; 16: 924-30.
26. Crosignani A, Battezzati PM, Setchell KD, et al. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study. Hepatology 1991; 13: 339-44.
27. Walker S, Rudolph G, Raedsch R, Stiehl A. Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology 1992; 102: 810-15.
28. Tint GS, Salen G, Shefer S. Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism. Gastroenterology 1986; 91: 1007-18.
29. Stiehl A, Raedsch R, Rudolph G, Walker S. Effect of ursodeoxycholic acid on biliary bile acid and bile lipid composition in gallstone patients. Hepatology 1984; 4: 107-11.
30. Marcus SN, Schteingart CD, Marquez ML, et al. Active absorption of conjugated bile acids in vivo. Kinetic parameters and molecular specificity of the ileal transport system in the rat. Gastroenterology 1991; 100: 212-21.
31. Jorgensen RA, Dickson ER, Hofmann AF, Rossi SS, Lindor KD. Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995; 36: 935-8.
32. van de Meeberg PC, Wolfhagen FHJ, van Berge Henegouwen G, et al. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: relation with biliary enrichment and biochemical response. J Hepatol 1996; 25: 887-94.
33. Stiehl A, Rudolph C, Sauer P, Theilmann L. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995; 23: 283-9.
34. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.
35. Lindor KD, Jorgensen R, Therneau TM, Smith C, Mahoney DW, Dickson ER. Comparison of three different doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. Hepatology 1997; 26: A1240(Abstract).
36. Muraca M, Vilei MT, Miami L, Petrin P, Antoniutti M, Pedrazzoli S. A simple method for the determination of lipid composition of human bile. J Lipid Res 1991; 32: 371-4.
37. Choudhuri G, Agarwal DK, Saraswat VA, Negi TS, Saxena R, Kapoor VK. Is duodenal bile representative of gallbladder bile? A comparative study. Scand J Gastroenterol 1993; 28: 920-3.
38. Janowitz P, Swobodnik W, Wechsler JG, Zoller A, Kuhn K, Ditschuneit H. Comparison of gall bladder bile and endoscopically obtained duodenal bile. Gut 1990; 31: 1407-10.
39. Muraca M, Pazzi P, Vilei MT, et al. Routine determination of biliary lipid composition with the entero-test. Ann Chir 1994; 48: 197-200.
40. Crosignani A, Podda M, Battezzati PM, et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991; 14: 1000-7.
41. Batta AK, Salen G, Mirchandani R, et al. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol 1993; 88: 691-700.
42. Heuman DM, Mills AS, McCall J, Hylemon PB, Pandak WM, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology 1991; 100: 203-11.
43. Pazzi P, Puviani AC, Libera MD, et al. Bile salt-induced cytotoxicity and ursodeoxycholate cytoprotection: in-vitro study in perfused rat hepatocytes. Eur J Gastroenterol Hepatol 1997; 9: 703-9.
44. Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 1986; 19: 57-69.
45. Guldutuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholale. Gastroenterology 1993; 104: 1736-44.
46. Heuman DM, Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994; 106: 1333-41.
47. Galan AI, Jimenez R, Munoz ME, Gonzalez J. Effects of ursodeoxycholate on maximal biliary secretion of bilirubin in the rat. Biochem Pharmacol 1990; 39: 1175-80.